Novartis takes EU lead in oral MS drug market
This article was originally published in Scrip
Novartis's oral MS drug fingolimod (Gilenya) has been recommended for marketing approval by the EU's Committee for Medicinal Products for Human Use (CHMP) on 20 January, putting it in line to be the first oral MS drug in the EU market dominated by inconvenient injectables. Competing oral drug, Merck KGaA (Serono)'s cladribine tablets, was rejected for a second time by the committee on cancer safety issues.
You may also be interested in...
The US Food and Drug Administration recently signalled its desire to work more closely with other drug regulators in assessing the quality of pharmaceutical manufacturing facilities around the world.
It seems as if the US FDA is softening its stance on assessing the quality of pharmaceutical manufacturing facilities around the world in future, with an apparent desire to work more closely with other drug regulators. However, incorporating the regulators from countries such as India, China and Japan into a global inspectorate still looks problematical.
Large pharmaceutical companies and Médecins sans Frontières may not often see eye-to-eye over access to medicines in poor countries. But it seems as if industry and the humanitarian body, a prominent critic, do agree that competition works in improving access to vaccines, even though they don't agree about the mechanisms of price setting.